CN116083590B - Gene detection kit and preparation method and application thereof - Google Patents
Gene detection kit and preparation method and application thereof Download PDFInfo
- Publication number
- CN116083590B CN116083590B CN202310287150.4A CN202310287150A CN116083590B CN 116083590 B CN116083590 B CN 116083590B CN 202310287150 A CN202310287150 A CN 202310287150A CN 116083590 B CN116083590 B CN 116083590B
- Authority
- CN
- China
- Prior art keywords
- cprdx1
- clcp1
- canine
- kit
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 5
- 238000001514 detection method Methods 0.000 title abstract description 24
- 108090000623 proteins and genes Proteins 0.000 title abstract description 15
- 241000282465 Canis Species 0.000 claims abstract description 36
- 102100027043 Discoidin, CUB and LCCL domain-containing protein 2 Human genes 0.000 claims abstract description 27
- 101000911787 Homo sapiens Discoidin, CUB and LCCL domain-containing protein 2 Proteins 0.000 claims abstract description 27
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 23
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 21
- 238000003745 diagnosis Methods 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- 210000005075 mammary gland Anatomy 0.000 claims description 6
- 108010085238 Actins Proteins 0.000 claims description 3
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 12
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101710132772 Peroxidase 1 Proteins 0.000 description 2
- 102000007456 Peroxiredoxin Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000011976 chest X-ray Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000010827 pathological analysis Methods 0.000 description 2
- 108030002458 peroxiredoxin Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100181504 Mus musculus Clc gene Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000007295 breast benign neoplasm Diseases 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of biological diagnosis, and particularly relates to a gene detection kit and a preparation method and application thereof. The invention discloses application of detecting expression levels of CLCP1 and CPRDX1 in preparing products for diagnosing canine breast tumor and a related detection kit. The kit can be used as one of means for diagnosing canine breast tumor, has the advantages of rapid and convenient detection, high detection sensitivity, good specificity and low cost, can meet most detection requirements, and has wide application range.
Description
Technical Field
The invention belongs to the technical field of biological diagnosis, and particularly relates to a gene detection kit and a preparation method and application thereof.
Background
Canine mammary tumor (Canine mammary tumor) is a common group of diseases in dogs, the cause of which is complex and the pathogenesis of which is not yet clear. Breast tumors are the most common tumor diseases of non-sterile female dogs, accounting for 50% -70% of all tumor diseases; about 50% of canine breast tumors are malignant, 50% are benign; some benign breast tumors may become malignant as the course of the disease progresses; the older the age, the higher the tumor risk; the age of onset of large dogs may be less than that of small dogs; the larger the tumor, the higher the probability of malignancy, the greater the difficulty of treatment, the more painful the animal-!
Currently, there are 5 main methods for diagnosis of canine breast tumors. Firstly, palpating in the breast areas, performing palpating examination on all the breast areas of dogs and dogs, and confirming the number and the size of the tumor; second, cytological examination confirms that the tumor growing in the mammary region is indeed a breast tumor, but not other more malignant tumors; thirdly, a hematological examination and a urine routine examination are needed for the aged animals to be comprehensively examined by blood and urine to evaluate animal body conditions; fourth, abdomen B ultrasonic and chest X-ray examination: the morphology of main organs of the abdominal cavity and the thoracic cavity can be evaluated before operation, and obvious metastasis and abnormality exist; fifth, CT, compared to chest X-ray, can evaluate the presence or absence of smaller metastatic nodules. These diagnostic methods are costly and require high personnel. Therefore, there is an urgent need to develop a conventional method for detecting canine breast tumor.
Disclosure of Invention
The invention aims to solve the technical problems that firstly, a marker which is suitable for diagnosing canine breast tumor is screened; on the basis, a gene kit for detecting canine breast tumor is developed.
Accordingly, in one aspect, the invention provides a canine breast tumor diagnostic marker, which is CLCP1 and CPRDX1.
In yet another aspect, the invention also provides a canine breast tumor diagnostic kit comprising reagents for detecting CLCP1 and CPRDX1 expression levels.
Preferably, the reagents described in the present invention include primers that specifically amplify CLCP1 and CPRDX1.
Preferably, the primers for specifically amplifying CLCP1 and CPRDX1 according to the present invention are as follows:
CLCP1-F：5’-cttggtacgagctcggatcc-3’；
CLCP1-R：5’-cgtacacccttgctccgatt-3’；
CPRDX1-F：5’-ttgctttcagtgacagggca-3’；
CPRDX1-R：5’-acagagcgaccaacaggaag-3’。
preferably, the PCR reaction solution of the invention further comprises a specific amplification primer of the internal reference gene beta-actin, and the sequences of the primer and the probe are as follows:
β-actin-F：5’-aagtaccccattgagcacgg-3’；
β-actin-R：5’-catacagggacaggacagcc-3’。
in still another aspect, the invention also provides application of the canine mammary gland tumor diagnosis marker in preparing a canine mammary gland tumor diagnosis reagent.
The invention screens the marker for diagnosing the canine breast tumor by the technical means of bioinformatics and existing molecular biology. CLCP1 and CPRDX1 were selected as markers from the large number of screens. On the basis, the invention provides application of detecting the expression levels of CLCP1 and CPRDX1 in preparing products for diagnosing canine breast tumor and a related detection kit.
Compared with the existing detection means of the canine mammary tumor, the kit provided by the invention has the advantages of rapidness and convenience in detection, high detection sensitivity, good specificity, low cost, capability of meeting most detection requirements, wide application range and the like.
Drawings
FIG. 1 shows the results of measurement of the expression level of CLCP1 and CPRDX1 in canine mammary tumor.
Detailed Description
The present invention is further illustrated below with reference to specific examples, which are not intended to limit the invention in any way. Unless specifically stated otherwise, the reagents, methods and apparatus employed in the present invention are those conventional in the art. Reagents and materials used in the following examples are commercially available unless otherwise specified.
Through extensive and intensive research, the inventor detects the expression level of related genes in canine mammary gland tumor through bioinformatics technology and molecular biology technology, discovers genes with obvious expression difference, discusses the relationship between the genes and canine mammary gland tumor occurrence, and thereby searches better ways and methods for canine mammary gland tumor detection and targeted therapy. Through extensive research and screening, 2 proteins similar to human mesolymphocyte cytoplasmic protein 1 (lymphocyte cytosolic protein, LCP 1) (GenBank: DR107736.1, shown in SEQ ID NO. 1) and peroxidase 1 (peroxiredoxin 1, PRDX 1) (GenBank: DR103789.1, shown in SEQ ID NO. 2) were screened. They were designated in this study as canine lymphocyte cytoplasmic protein 1 (Canine lymphocyte cytosolic protein, clcp 1) and canine peroxidase 1 (Canine peroxiredoxin, cprdx 1).
By detection analysis, CLCP1 and CPRDX1 were highly expressed in canine breast tumors. Further experiments prove that the growth of canine breast tumors can be influenced by regulating the expression levels of CLCP1 and CPRDX1, and the CLCP1 and CPRDX1 are suggested to be used as drug targets for diagnosis or treatment of canine breast tumors.
"biomarker" and "marker" can be equivalently replaced, referring to a molecular indicator having a specific biological property, biochemical characteristic, or aspect, that can be used to determine the presence or absence of a particular disease or condition and/or the severity of a particular disease or condition.
Example 1 detection of CLCP1 and CPRDX1 in canine mammary tumors
1.1 sample collection
The method comprises the steps of selecting a canine breast tumor case which is treated in an animal hospital in Guangzhou city and subjected to pathological diagnosis, carrying out aseptic operation, reserving part of cancer tissues and other normal tissues (about 2-5 cm away from the cancer tissues), sub-packaging the cancer tissues and the other normal tissues in a freezing tube, and immediately storing the frozen tissue in liquid nitrogen. All affected animals were subjected to pathological diagnosis by the senior pathologist, did not suffer from other tumors prior to inclusion in the study, and were not treated with radiation or chemotherapy. Of which 5 malignant tumor tissues and paracancerous tissues were selected for the study.
1.2 extraction of Total RNA from tissues
(1) 1ml Trizol reagent (Takara Co.) was used to lyse the tissue per 50-100 mg of tissue;
(2) Transferring Trizol lysate of the above tissue into an EP tube, and standing at room temperature for 5 min;
(3) In the above EP tube, chloroform was added in an amount of 0.2ml of chloroform per 1ml of Trizol, the EP tube was capped, the tube was shaken vigorously in the hand for 15 seconds, and after leaving at room temperature for 2 to 3 minutes, 12000g (2 to 8 ℃) was centrifuged for 15 minutes;
(4) The upper aqueous phase was removed and placed in a fresh EP tube, isopropanol was added in an amount of 0.5ml of isopropanol per 1ml of Trizol, and after 10 minutes at room temperature, 12000g (2-8 ℃) was centrifuged for 10 minutes;
(5) Discarding the supernatant, adding 1ml of 75% ethanol into each 1ml of Trizol for washing, mixing by vortex, centrifuging for 5 minutes at 12000g (2-8 ℃), and discarding the supernatant;
(6) Allowing the precipitated RNA to naturally dry at room temperature;
(7) Dissolving the RNA precipitate by using RNase-free water;
(8) The extracted RNA samples were assayed for concentration and OD260/OD280 ratio to control sample quality, and samples with OD260/OD280 ratios between 1.8 and 2.0 were selected for subsequent testing.
1.3 primer design
Primer design was performed using Primer 5.0 software based on the CLCP1 (SEQ ID NO. 1) and CPRDX1 (SEQ ID NO. 2) sequences. And (3) obtaining a plurality of pairs of specific primers, and finally respectively determining a group of optimal primers through comparison and screening. The method comprises the following steps:
CLCP1-F：5’-cttggtacgagctcggatcc-3’；
CLCP1-R：5’-cgtacacccttgctccgatt-3’；
CPRDX1-F：5’-ttgctttcagtgacagggca-3’；
CPRDX1-R：5’-acagagcgaccaacaggaag-3’；
β-actin-F：5’-aagtaccccattgagcacgg-3’；
β-actin-R：5’-catacagggacaggacagcc-3’。
1.4 reverse transcription reaction
The reverse transcription assay system was carried out at 20. Mu.l, with reference to EasScript First-Strand cDNA Synthesis SuperMix (catalog number AE301-02, beijing full gold Biotechnology Co., ltd.).
1.5 fluorescent quantitative PCR reactions
The reverse transcription reaction is taken for real-time fluorescence quantitative PCR operation, and the reaction system is 20 μl: mu.l SYBR Premix, 2. Mu.l cDNA template, 0.6. Mu.l upstream and downstream primer each and 6.8. Mu.l DEPC water. Experiments were performed using 7500 fluorescent quantitative PCR from ABI, usa, with reaction settings: pre-denaturation at 95℃for 30s, annealing at 60℃for 20s, elongation at 72℃for 30s,40 cycles.
Wherein 2 is -△△Ct The expression of the target genes of the experimental group and the control group is expressed by the following formula: Δct=ct (target gene) -Ct (reference), ΔΔct= Δct Experimental group －△Ct Control group . Ct is the diffusion cycle passed when the real-time fluorescence intensity of the reaction reaches a set thresholdThe number of loops, in which case diffusion increases in logarithmic phase. The expression levels of CLCP1 and CPRDX1 were calculated. Wherein the internal reference is beta-actin (shown as SEQ ID NO. 3).
1.6 detection results
The specific results are shown in FIG. 1. From the figure, it can be seen that CLCP1 and CPRDX1 were significantly up-regulated in canine breast tumor expression levels.
Example 2 detection of clinical samples by the kit
The expression levels of CLCP1 and CPRDX1 in the serum of 30 dogs and 30 healthy dogs were detected using the detection kit of example 2. Regression analysis was performed on the detection results using origin software, wherein single detection index results, two index combinations, and three index combinations of CLCP1 and CPRDX1 are shown in table 1.
The results show that the P value of each index and the P value of the combined index are less than 0.05, which indicates that each detection index is obviously related to the canine breast tumor prediction. The combined prediction accuracy of CLCP1 and CPRDX1 reaches 96% (area under ROC curve) and is higher than that of a single detection index. Thus, the combined detection of CLCP1 and CPRDX1 has significant advantages in canine breast tumors.
TABLE 1 analysis of test results
| Detecting a variable | Sensitivity of | Specificity (specificity) | Area under ROC curve |
| CLCP1 | 0.72 | 0.79 | 0.83 |
| CPRDX1 | 0.78 | 0.75 | 0.84 |
| CLCP1+CPRDX1 | 0.95 | 0.96 | 0.96 |
The above examples are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above examples, and any other changes, modifications, substitutions, combinations, and simplifications that do not depart from the spirit and principle of the present invention should be made in the equivalent manner, and the embodiments are included in the protection scope of the present invention.
Claims (6)
1. The canine mammary gland tumor diagnosis marker is characterized in that the markers are CLCP1 and CPRDX1; the sequence of the marker CLCP1 is shown in SEQ ID NO. 1; the sequence of the marker CPRDX1 is shown as SEQ ID NO. 2.
2. A canine breast tumor diagnostic kit, which is characterized in that the kit comprises reagents for detecting the expression levels of CLCP1 and CPRDX1; the sequence of the CLCP1 is shown as SEQ ID NO. 1; the sequence of the CPRDX1 is shown as SEQ ID NO. 2.
3. The kit of claim 2, wherein the reagents comprise primers that specifically amplify CLCP1 and CPRDX1.
4. The kit according to claim 3, wherein the primers for specifically amplifying CLCP1 and CPRDX1 are as follows:
CLCP1-F：5’-cttggtacgagctcggatcc-3’；
CLCP1-R：5’-cgtacacccttgctccgatt-3’；
CPRDX1-F：5’-ttgctttcagtgacagggca-3’；
CPRDX1-R：5’-acagagcgaccaacaggaag-3’。
5. the kit according to claim 2, further comprising specific amplification primers for the reference gene β -actin, the primer sequences being as follows:
β-actin-F：5’-aagtaccccattgagcacgg-3’；
β-actin-R：5’-catacagggacaggacagcc-3’。
6. use of the canine breast tumor diagnostic marker of claim 1 in the preparation of a canine breast tumor diagnostic reagent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310287150.4A CN116083590B (en) | 2023-03-23 | 2023-03-23 | Gene detection kit and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310287150.4A CN116083590B (en) | 2023-03-23 | 2023-03-23 | Gene detection kit and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116083590A CN116083590A (en) | 2023-05-09 |
| CN116083590B true CN116083590B (en) | 2024-03-22 |
Family
ID=86188166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310287150.4A Active CN116083590B (en) | 2023-03-23 | 2023-03-23 | Gene detection kit and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116083590B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2734643A2 (en) * | 2011-07-19 | 2014-05-28 | Koninklijke Philips N.V. | Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression |
| CN106093397A (en) * | 2016-06-13 | 2016-11-09 | 厦门大学 | Kit for breast cancer with glutathion peroxidase 3 as mark |
| CN109022575A (en) * | 2018-07-06 | 2018-12-18 | 华南农业大学 | A kind of molecular marker can be used for dog Diagnosis of Breast Tumor and Index for diagnosis |
| CN111948395A (en) * | 2020-08-19 | 2020-11-17 | 复旦大学附属金山医院 | Quadruple marker for diagnosing immune regulation subtype of triple negative breast cancer and application thereof |
| CN114664440A (en) * | 2021-09-27 | 2022-06-24 | 上海爱谱蒂康生物科技有限公司 | Prediction method and application of breast cancer metastasis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070105105A1 (en) * | 2003-05-23 | 2007-05-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| WO2008154333A2 (en) * | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | Mir-34 regulated genes and pathways as targets for therapeutic intervention |
| TWI470082B (en) * | 2010-05-04 | 2015-01-21 | Univ Nat Taiwan | Method for identifying canine cancer |
-
2023
- 2023-03-23 CN CN202310287150.4A patent/CN116083590B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2734643A2 (en) * | 2011-07-19 | 2014-05-28 | Koninklijke Philips N.V. | Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression |
| CN106093397A (en) * | 2016-06-13 | 2016-11-09 | 厦门大学 | Kit for breast cancer with glutathion peroxidase 3 as mark |
| CN109022575A (en) * | 2018-07-06 | 2018-12-18 | 华南农业大学 | A kind of molecular marker can be used for dog Diagnosis of Breast Tumor and Index for diagnosis |
| CN111948395A (en) * | 2020-08-19 | 2020-11-17 | 复旦大学附属金山医院 | Quadruple marker for diagnosing immune regulation subtype of triple negative breast cancer and application thereof |
| CN114664440A (en) * | 2021-09-27 | 2022-06-24 | 上海爱谱蒂康生物科技有限公司 | Prediction method and application of breast cancer metastasis |
Non-Patent Citations (5)
| Title |
|---|
| Common plasma protein marker LCAT in aggressive human breast cancer and canine mammary tumor;Hyoung-Min Park等;BMB Rep;第53卷(第12期);第664-669页 * |
| GenBank：DR103789.1;NCBI;NCBI GenBank;第1-799页 * |
| GenBank：DR107736.1;NCBI;NCBI GenBank;第1-723位 * |
| 基于蛋白质组学的乳腺癌标志物筛选及其应用;邓克瑜等;中国现代医生;第60卷(第20期);第40-45, 50页 * |
| 蒙药乳腺-Ⅰ号对大鼠乳腺增生组织中Prdx-1、GSTP和SOD蛋白表达的影响;王忠超等;中国老年学杂志;第39卷;第630-633页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116083590A (en) | 2023-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008070301A9 (en) | Predicting lung cancer survival using gene expression | |
| CN108624688B (en) | Application of hsa _ circ _0012755 as prostate cancer molecular target in preparation of medicines and kits | |
| TW201217786A (en) | Methods and kits for the diagnosis of prostate cancer | |
| CN111560435A (en) | DNA methylation kit for colorectal cancer detection, and use method and application thereof | |
| CN110964823A (en) | DNA methylation kit for colorectal cancer detection and detection method | |
| CN108753980A (en) | A kind of kit for screening of the metastatic screening of the small papillary carcinoma of thyroid gland | |
| CN116083590B (en) | Gene detection kit and preparation method and application thereof | |
| JP7187081B2 (en) | Methods for early diagnosis and post-treatment monitoring of breast cancer using liquid biopsy multiplex oncogene biomarkers | |
| KR102052398B1 (en) | Biomarkers for diagnosis of prostate cancer and uses thereof | |
| CN111118158A (en) | Method, primer, probe and kit for detecting relative expression quantity of RBM5 gene | |
| CN115961038A (en) | Composition for detecting gastric cancer, kit and application thereof | |
| JP2019531738A (en) | Indoleamine-2,3-dioxygenase assay for the diagnosis and prognosis of prostate cancer | |
| Bozhenko et al. | Mammaglobin in peripheral blood and the tumor of breast cancer patients | |
| KR102550113B1 (en) | Biomarkers for diagnosis of prostate cancer and uses thereof | |
| KR102585974B1 (en) | A method to calculate a diagnostic score for a prostate cancer and use thereof | |
| CN109022586A (en) | One kind blood plasma miRNA marker relevant to cervical carcinoma auxiliary diagnosis and its application | |
| CN108929909A (en) | A kind of kit for screening of the metastatic screening of the small papillary carcinoma of thyroid gland | |
| RU2743223C1 (en) | Method of differential diagnosis of glial brain tumors | |
| KR102395129B1 (en) | Method of providing information for Castrate Resistant Prostate Cancer diagnosis and kit for diagnosing Castrate Resistant Prostate Cancer | |
| CN116497121A (en) | Gene detection kit and application thereof | |
| CN109182514A (en) | Pulmonary cancer diagnosis or transfer diagnosis marker LncRNA Loc729658 and kit and its application | |
| CN117265112B (en) | Digital micro-droplet RNA amplification detection system for prostate cancer and application of PCA3 gene in system | |
| CN112176060B (en) | Plasma non-coding RNA and primer set for detecting expression level thereof and colorectal cancer detection kit | |
| CN110144352B (en) | Molecular marker for early diagnosis of orthopedic diseases | |
| WO2024001602A1 (en) | Composition for detecting gastric cancer, kit, and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20240226 Address after: 071799 9th Floor, B2, Fenghua Valley, Huawangcheng, Xiong'an District, Rongcheng China (Hebei) Pilot Free Trade Zone, Baoding City, Hebei Province (self declared) Applicant after: Xiong'an Miaoxin Medical Testing Co.,Ltd. Country or region after: China Address before: No. 25-2nd Floor, No. 111-119 Yinghua Street, Xiaogang Bay, Nanzhou Road, Haizhu District, Guangzhou City, Guangdong Province, 510290 Applicant before: Guangzhou Airen Biopharmaceutical Technology Co.,Ltd. Country or region before: China |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |